Phrontline Biopharma reports 75% response rate for TJ101 in urothelial cancer
AI Summary- Phrontline Biopharma presented preliminary TJ101 results across several advanced solid tumors.
- Six of eight evaluable urothelial carcinoma patients achieved partial responses, representing 75%.
- TJ101 Phase Ib began with the first patient dosed after the ESMO presentation.